Overview

Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

Status:
Not yet recruiting
Trial end date:
2024-07-26
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
Phase:
Phase 4
Details
Lead Sponsor:
Biohaven Pharmaceuticals, Inc.